A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The purpose of the study is to learn more about how the body responds to standard treatment (chemoradiation and chemotherapy). The study will use the results of testing down on participants' blook, tissue, and scans to learn more about how people with rectal cancer respond to chemoradiation and chemotherapy treatment and if it is useful for predicting whether a person's cancer get better, gets worse, or stats the same after treatment.
Eligibility criteria
Qualifiers
18 years of age or older on day of signing informed consent.
Have a histologically confirmed diagnosis of invasive adenocarcinoma of the rectum with no known mismatch repair deficiency or Her2 amplification.
Induction fluoropyrimidine (capecitabine [preferred] or 5-FU) based chemoradiation
With plan for consolidative CAPEOX, FOLFOX, or FOLIRINOX
Disqualifiers
Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.
Patients with prior external beam radiation therapy to the pelvis or brachytherapy seed implantation of the prostate.
Patients who are pregnant or breastfeeding.
Men or women not using effective contraception.
Trial design
Treatments tested in this trial
- Endoscopy
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov